Kyowa Hakko Kirin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Kyowa Hakko Kirin Co., Ltd.
Type Public KK
Traded as TYO: 4151
Nikkei 225 Component
Founded July 1, 1949
Headquarters Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
Key people Nobuo Hanai, (CEO and President)

$ 3.548 billion USD (FY 2013)

Increase (¥ 340.61 billion JPY) (FY 2013)
Net income

$ 31.32 million USD (FY 2013)

Increase (¥ 30.07 billion JPY) (FY 2013)
Employees 7,152 (consolidated) (as of December 31, 2013)
Parent Kirin Holdings Company, Limited
Subsidiaries 47 (33 in Japan and 14 overseas countries)
Website Official website
Footnotes / references

Kyowa Hakko Kirin Co., Ltd. (協和発酵キリン株式会社 Kyōwa Hakkō Kirin Kabushiki Kaisha?) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4] [5]


On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.

On July 11, 2014, the KHK subsidiary, ProStrakan Group, acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6]

Business segments and products[edit]


External links[edit]